Invasive fungal disease (IFD) confers a substantial risk for morbidity and mortality to immunocompromised patients. Invasive aspergillosis (IA) is the most common IFD caused by moulds but the prevalence of other rare mould diseases, such as mucormycosis, hyalohyphomycosis and phaeohyphomycosis, may be increasing. Treatments are available for IA, but evidence to support efficacy and safety of antifungal agents for rare IFDs, or for IFDs in special patient populations, is limited or lacking. The VITAL trial was conducted to assess the efficacy and safety of isavuconazole for the treatment of patients with IA and renal impairment, or with IFDs caused by rare moulds, yeasts or dimorphic fungi. These patients stand to benefit most from a new treatment option but are unlikely to be included in a randomised, controlled trial. In this article, we review the challenges faced in the design and conduct of the VITAL trial. We also review the findings of VITAL, which included evidence of the efficacy and safety of isavuconazole. Finally, we consider the importance of trials such as VITAL to inform therapeutic decision making for clinicians faced with the challenge of treating patients with rare IFDs and as one paradigm of how to determine efficacy and safety of new drugs for rare and resistant infections without a suitable comparator. K E Y W O R D S aspergillosis, cryptococcosis, dimorphic fungi, invasive fungal diseases, isavuconazole, mucormycosis, rare moulds, yeasts | 421 PERFECT ET al.
| INTRODUC TI ON
Invasive fungal diseases (IFDs) confer a substantial risk for morbidity and mortality, especially in patients who are immunocompromised, such as those being treated for haematological malignancies or those undergoing solid organ transplantation. 1, 2 Among IFDs caused by moulds, invasive aspergillosis (IA) is the most common; however, the prevalence of other rare mould infections, such as mucormycosis, hyalohyphomycosis and phaeohyphomycosis, may be increasing. 3, 4 Treatment options for IA include triazole antifungal agents (eg voriconazole or isavuconazole), amphotericin B formulations and echinocandins, 5, 6 but there is a scarcity of strong evidence to support any pharmacological treatment for many rare IFDs.
Voriconazole is approved to treat fusariosis and scedosporiosis, 7, 8 and its use is featured in treatment guidelines, 9 but susceptibility of those pathogens to triazole antifungal agents is not predictable and clinical failures remain common. The recommendation to treat mucormycosis with liposomal amphotericin B is based largely on animal studies 10 and posaconazole has mainly been studied in the salvage setting. 11, 12 Amphotericin B formulations are also recommended for serious cryptococcal disease and other endemic mycoses; [13] [14] [15] [16] however, their intravenous-only formulations pose a challenge for extended treatment and use of these agents may be limited by nephrotoxicity. 17, 18 Various other monomicrobial and mixed fungal infections are sufficiently rare or refractory to tested antifungal agents such that no specific treatment recommendations exist.
The VITAL trial was designed and conducted to determine the efficacy and safety of isavuconazole (active moiety of the prodrug isavuconazonium sulphate) for the treatment of IA in patients with renal impairment, or in patients with IFDs caused by rare moulds, including Mucorales spp., yeasts or dimorphic fungi. This article provides an overview of the planning, performance, challenges and lessons of the VITAL trial, which has previously reported the efficacy and safety of isavuconazole for the treatment of mucormycosis, 19 cryptococcosis and other endemic mycoses, 20 other rare moulds and yeasts 21 and mixed fungal infections. 22 
| CHALLENG E S IN THE DE S I G N AND CONDUC T OF THE VITAL TRIAL
Compared with clinical trials of treatments for common diseases, trials for rare diseases pose some unique challenges. For example a systematic study showed that trials of rare conditions enrolled approximately half the number of patients, lasted approximately 50% longer, and were terminated at approximately twice the rate of trials for non-rare conditions. 23 The design and conduct of the VITAL trial reflected the impact of these challenges.
Although clinical trials conducted in common diseases usually use a randomised controlled parallel group design, the low number of cases and the heterogeneity of underlying conditions and causative pathogens in patients with rare fungal diseases limits the ability to conduct a controlled trial versus a standard-of-care comparator within a reasonable length of time. An optimistic estimate for the time required to conduct such a study in patients with mucormycosis was more than 10 years, 24 so studies of IFDs that are even more rare would be expected to take considerably longer. In addition, no standard-of-care treatments exist for many rare IFDs, and even when such a treatment may be available, differences in treatment administration (eg route, schedule) may preclude study blinding.
Consequently, as with many trials of rare diseases, 23 From a sponsor's logistical perspective, low patient numbers make finding and retaining appropriate study sites challenging. As a result, these trials are often conducted in selected medical centres across wide geographical areas. However, challenges in organisation, management and costs of trials increase as a function of the number of study sites, irrespective of whether those sites actually enrol eligible patients. To balance these competing factors, the study was planned to be conducted at approximately 150 centres globally.
Conducting trials of rare conditions in selected medical centres across a wide geographical area is usually associated with variation in standard-of-care and regional expertise that might influence and complicate diagnosis and assessment of outcome measures. To address this issue, the VITAL trial included a Data Review Committee (DRC). The DRC consisted of three experts in the field of fungal infections in immunocompromised hosts, and was independent of the trial sponsor and the study investigators. The DRC was established to adjudicate the diagnosis and categorisation of each patient's IFD at enrolment, and to evaluate study endpoints.
A key aim of the VITAL trial was to determine the efficacy and Patients enrolled in the VITAL trial required primary therapy at enrolment; patients with clear documentation of disease progression or failure to improve clinically despite receiving at least 7 days of prior standard antifungal regimen were also enrolled. Patients initially assessed with possible IFD for whom criteria for probable or proven IFD were not met within 7 days after initiation of study drug were excluded from efficacy analyses. The VITAL trial included only patients aged 18 years or older because safety, efficacy and pharmacokinetics of isavuconazole had not been assessed in paediatric patients. Although isavuconazole may shorten the QT interval (without any obvious untoward effects), 27 patients were also required to have a rate-corrected QTc interval of <500 ms. Concurrent treatments with strong inhibitors or inducers of cytochrome P450 enzymes were not allowed due to the potential for drug-drug interactions, although such interactions may be less prominent with isavuconazole compared with some other triazole antifungal agents. 28 To prevent obscuring any study-treatment effects, other non-study systemic antifungal treatments were not permitted from the first dose of isavuconazole through the last follow-up visit. Isavuconazole is administered as water-soluble prodrug, whereas for IA and most IFD, all available parenteral treatment options at the time of the VITAL study were contraindicated in patients with renal impairment.
For patients with possible, probable or proven IA, 26 an estimated creatinine clearance (CrCl) of <50 mL/min (Cockcroft-Gault formula) was originally required; a later amendment to reflect clinical practice guidelines defined renal impairment as an estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73 m 2 (patients enrolled prior to the amendment were not excluded). 29 Determining appropriate endpoints and the timeline for assessments is a key challenge of clinical studies conducted in rare conditions. Refractory and rare IFDs occur in a select group of patients with underlying conditions that in turn confer a high risk of treatment failure. Therefore, any measure of successful outcome in IFDs within these patients can be confounded by complications of the underlying disease, making attributable mortality and morbidity difficult to quantify. 30 There have been substantial efforts to provide guidelines to assess outcomes, in which mycological, radiological and clinical outcomes are measured. 30 However, these recommendations are imprecise and may be complicated by differences in disease sites. Current consensus guideline recommendations for evaluating treatment responses in patients with IA indicate that the primary endpoint should be assessed at 6 weeks of treatment (ie 42 days), and a secondary endpoint should include an assessment at 12 weeks of treatment (ie, 84 days). 30 However, the optimal timing for assessments of responses in more rare IFDs is less clear.
Taking into account all the limited guidance available, the primary study endpoint for the VITAL trial was DRC-assessed overall response at Day 42; secondary endpoints included assessments of overall, clinical, radiological and mycological responses at Day 42, Day 84 and end of treatment (EOT), all-cause mortality at Days 42 and 84 and safety. Initially, the maximum treatment duration was set at 84 days. However, because no recommendations regarding duration of therapy exist for many rare IFDs, subsequent amendments extended the maximum duration to 180 days, and >180 days in cases where the investigator determined that the patient was deriving clinical benefit.
Overall response was defined as success (complete or partial) or failure (stable or progression) and was a composite of DRC-assessed 
3.
Radiological success required at least a 25% improvement from baseline at 42 days or at least a 50% improvement from baseline at 84 days; patients not meeting these criteria, or those with no post-baseline radiology available that showed baseline evidence of radiological disease or without radiology available at baseline, were ruled as failures.
Categorisation of outcome data is difficult in studies of rare IFDs.
Radiographs often do not change rapidly. The requirement for radiological resolution to interpret treatment success of some rare IFDs as "complete" presents another challenge. For example, imaging of pulmonary mucormycosis frequently shows cavitation resulting from localised tissue necrosis. 31 Inclusion of a control group for the VITAL trial was not feasible given the limitations discussed above, and the low numbers of patients in any study of rare diseases can limit the ability to develop any statistical power to form robust conclusions. However, in the absence of a control group, historical data can sometimes be used for studies of rare diseases, in accordance with guidance provided by the US Food and Drug Administration. 32 In the case of mucormycosis, a sufficient number of patients were enrolled in the VITAL trial to allow a subsequent case-matched analysis using mortality outcomes data from the FungiScope: Global Emerging Fungal Infection Registry (ClinicalTrials.gov identifier: NCT01731353), 33 as described in more detail elsewhere. 19 
| OVERVIE W OF RE SULTS FROM THE VITAL TRIAL
The 36 which was consistent with the most common underlying risk factors observed in the VITAL trial in patients with fusariosis alone. 21 All other pathogens in the VITAL trial were too rare to allow any meaningful comparisons with existing data. Among the patients with IA in the VITAL trial, those with renal impairment tended to be older than those without renal impairment. Two patients with mucormycosis, one patient with histoplasmosis, one patient with a mixed fungal infection (aspergillosis and mucormycosis) and one patient with IA without renal impairment continued treatment past the end of the study. These data suggest that the optimal treatment duration for many rare IFDs may be substantially longer than for IA.
| Baseline characteristics and treatment duration

| Efficacy
Among the different patient groups, rates of treatment success (overall response) at Day 42 ranged from 10.8% to 50.0%, and confirmed survival at Day 42 ranged from 62.2% to 100% ( Table 2 ). In the analysis of patients with only mucormycosis, 21 patients who received isavuconazole as primary treatment were matched with 33 case controls from the FungiScope registry. 19 Higher proportions of patients from the VITAL trial had proven mucormycosis and severe disease compared with the amphotericin B-treated controls (86% vs 61%, and 57% vs 39%, respectively). Despite that, the rates of survival in patients from the VITAL trial were similar in both crude and weighted analyses (67% vs 61%, and 67% vs 59%, respectively). Outcomes among patients with cryptococcosis or dimorphic mycoses were also notable, 20 as the rates of treatment success were within the range of those observed in previous studies assessing the efficacy of other triazole antifungal agents to treat subsets of these IFDs (38.9% to 94.4% [38] [39] [40] [41] [42] [43] ). Among patients with other emerging fungal infections, more than half of evaluable patients responded by EOT. 21 The overall success rate at EOT was considerably less for patients with mixed fungal infections;
still, two-thirds of patients in this group were confirmed alive at the end of the study. 22 In patients with IA, the rate of treatment 
| Safety and tolerability
| LE SSON S FROM THE VITAL TRIAL
Despite the challenges faced, the results of the VITAL trial provide evidence that an interventional trial to test a treatment for rare IFDs can be efficiently designed, conducted and communicated to the medical community. The VITAL trial has demonstrated efficacy of isavuconazole for the treatment of mucormycosis 19 and suggests that isavuconazole is also effective in the treatment of infections caused by Cryptococcus spp. and dimorphic fungi. 20 Although treatment successes were observed for some patients with IFDs caused by other rare fungal species 21 and mixed fungal species, 22 evidence for efficacy of isavuconazole in those groups is insufficient to allow any definitive conclusions, but form a basis that can be supplemented with data from future trials, case reports and database analyses. Evidence for efficacy of isavuconazole in patients with IA and renal impairment is also insufficient for any firm conclusions, but it suggests that there is no loss of efficacy or drug-specific safety concerns in those patients. Moreover, analysis of study data has allowed for the recruitment rates of several IFDs to be measured, which may help guide future studies of rare IFDs. The relatively low recruitment rates suggest that, as new broad-spectrum antifungals are developed, it may be advisable to start a clinical protocol for particular rare IFDs in early phase studies. In addition, the duration of treatment was extended to more than 180 days for a substantial number of patients who had been deemed by investigators to be deriving clinical benefit. Therefore, the optimal timing for assessing outcomes for treatments of rare IFDs still needs to be determined.
Assessing potential treatments for rare IFDs and in special patient populations will continue to pose a challenge for the foreseeable future. Nevertheless, it is crucial that such treatments for emerging IFDs and for IFDs in special patient populations are evaluated, 
